Pliant

Aditya Madhavan’s vocal concert streamed live on www.paalamtv.com during the 26th Margazhi utsavam 2023 of Mudhra. He is accompanied by Chidambaram Badrinath (violin), Punnur Arvind Kaushik (mridangam) and Kottayam Rohith Prasad (ghatam).…

<!-- Name:DistributionId Value:8828703 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8795634 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8786540 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8741346 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today…

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification Interim 12-week data expected in early 2023 SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE…

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today…

SOUTH SAN FRANCISCO, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today…

PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment PLN-74809 treatment effect was observed on top of standard of care therapy and as monotherapy PLN-74809 was well tolerated…